We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ARU-1801

News List

Aruvant partners with Lonza to manufacture sickle cell disease treatment pharmaceutical-technology
January 20, 2021
Clinical-stage biopharmaceutical firm Aruvant Sciences and Lonza have entered a strategic long-term manufacturing agreement for the former’s one-time investigational gene therapy for sickle cell disease (SCD), ARU-1801.
Aruvant Receives FDA Rare Pediatric Disease Designation for Sickle Cell Treatment americanpharmaceuticalreview
January 13, 2020
Aruvant announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to ARU-1801, Aruvant's investigational therapy for the treatment of sickle cell disease.